Ranbaxy, Dr. Reddy's To Benefit From Teva Skipping U.S. Lipitor Market
This article was originally published in PharmAsia News
Ranbaxy Laboratories and Dr. Reddy's Laboratories can expect a greater share of the U.S. market for a generic of Pfizer Inc.'s Lipitor (atorvastatin) after Teva Pharmaceuticals said it would shun that market.
You may also be interested in...
This month’s column covers deals announced between 1-23 April 2020.
Celltrion’s Truxima has become the first rituximab biosimilar, and just the second biosimilar overall, to be prequalified by the WHO.
EU MDR Panel Discussion: Why An Extra Year Is Not Really A Delay For The MDR – How To Survive Changing And Confusing Times
26 May 2020, the date that the Medical Device Regulation was originally due to apply in the EU, was a good time to take stock of where the medtech sector finds itself. Three of the most renowned and outspoken experts on the EU medical device regulatory system gave their views in this exclusive interview.